TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6430689

Group type: EXPERIMENTAL
Intervention: Compliance-improving strategies (patient counselling, special medication container, self-recording of medication intake and seizures, mailed reminders)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study: 30803749

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (4 g daily for 8 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 29396070

Group type: EXPERIMENTAL
Intervention: l-homoarginine (l-hArg) supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26792024

Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of HCA (2800 mg in water)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 20
Study: 25172769

Group type: EXPERIMENTAL
Intervention: CPAP plus best supportive care (BSC)
Number of subjects: 278

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 278
Study: 23285095

Group type: EXPERIMENTAL
Intervention: Amodiaquine + sulfadoxine‐pyrimethamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: None (control group not specified)
Number of subjects: 0
Study: 20307827

Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention (support and incentives to save money toward secondary education)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 277
Study: 17971533

Group type: EXPERIMENTAL
Intervention: Adaptive treatment strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential randomization
Number of subjects: 0
Study: 15576850

Group type: EXPERIMENTAL
Intervention: PON1 genotypes (L55M, Q192R, -107C/T, -162A/G, -824G/A, and -907G/C)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: PON1 levels
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: PON1 activity (paraoxonase, diazoxonase, arylesterase)
Number of subjects: 302
Study: 12167681

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 to 240 units)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 10376916

Group type: EXPERIMENTAL
Intervention: 48 degrees C
Number of subjects: 138

Group type: COMPARATOR
Intervention: 60 degrees C
Number of subjects: 138
Study: 8897081

Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g b.i.d. for 5 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (absence of sucralfate)
Number of subjects: 14
Study: 1642342

Group type: EXPERIMENTAL
Intervention: 8 mg intravenous bolus of dexamethasone
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 6427477

Group type: EXPERIMENTAL
Intervention: 1 mg luteinizing hormone releasing hormone agonist daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: 3 mg diethylstilbestrol per day
Number of subjects: 23
Study: 30865980

Group type: EXPERIMENTAL
Intervention: Fortified breast milk until 52 weeks of gestational age (GA)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Breastfeeding according to recommendations in developing countries
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 4-6 months or low protein follow-up formulas
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Low-protein formulas during infancy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High-protein intake during the first 2 years
Number of subjects: 158
Study: 29327313

Group type: EXPERIMENTAL
Intervention: Somatosensory therapy (four types of exercises: touch, proprioception, vibration, stereognosis)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Somatosensory therapy
Number of subjects: 59
Study: 26785711

Group type: EXPERIMENTAL
Intervention: Calorie-restricted, semi-vegetarian diet with vitamin D and dietary supplements (fish oil, lipoic acid, omega-3 polyunsaturated fatty acids, resveratrol, multivitamin complex)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Calorie-restricted, semi-vegetarian diet with vitamin D and dietary supplements
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Weekly administration of 5000 IU vitamin D
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dietary restriction only
Number of subjects: 43
Study: 24628753

Group type: EXPERIMENTAL
Intervention: Routine care plus EEG (microEEG)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 149
Study: 22784038

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate and emtricitabine (TDF-FTC)
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1219
Study: 19944713

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 615

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 615
Study: 18763437

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study: 16536100

Group type: EXPERIMENTAL
Intervention: Perineal hair cutting
Number of subjects: 458

Group type: COMPARATOR
Intervention: Perineal shaving
Number of subjects: 458
Study: 12421066

Group type: EXPERIMENTAL
Intervention: Parafoveal preview of target characters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parafoveal preview of graphemically similar characters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phonological relationship between previewed radicals and subsequently viewed targets
Number of subjects: 0
Study: 9932949

Group type: EXPERIMENTAL
Intervention: BIL transmission of tics
Number of subjects: 111

Group type: COMPARATOR
Intervention: SP group
Number of subjects: 111

Group type: COMPARATOR
Intervention: UNL group
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: BIL group
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: BIL patients
Number of subjects: 111
Study: 7810529

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cellulose triacetate membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cuprophan membrane
Number of subjects: 10
Study: 2318913

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide suppositories (150 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous metoclopramide (150 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide suppositories
Number of subjects: 9
Study: 381860

Group type: EXPERIMENTAL
Intervention: Metoprolol (234 +/- 22 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pindolol (25 +/- 2 mg/day)
Number of subjects: 31
Study: 31471863

Group type: EXPERIMENTAL
Intervention: BAL101553 administered as a 48-h IV infusion at a maximum tolerated dose (MTD) of 70 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAL101553 oral administration on Days 15–21 of cycle 2
Number of subjects: 0
Study: 30548953

Group type: EXPERIMENTAL
Intervention: Alcohol consumption intervention in community sports clubs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28988746

Group type: EXPERIMENTAL
Intervention: Alfaxalone 2 mg kg−1 (A2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alfaxalone 1 mg kg−1 (A1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline 0.1 mL kg−1 (S)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alfaxalone 1 mg kg−1 (A1) and Alfaxalone 2 mg kg−1 (A2)
Number of subjects: 10
Study: 25370598

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 0
Study: 23569096

Group type: EXPERIMENTAL
Intervention: Adult-size dishware
Number of subjects: 42

Group type: COMPARATOR
Intervention: Child-size dishware
Number of subjects: 42
Study: 21304250

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 99
Study: 19835678

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 16923004

Group type: EXPERIMENTAL
Intervention: Permanent bipolar active pacing lead, placed transcutaneously in the right ventricle and connected to an external pacing generator (n = 23, external lead group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional pacing wire/catheter (n = 26, reference group)
Number of subjects: 49
Study: 15242414

Group type: EXPERIMENTAL
Intervention: Endurance training (bicycling at 70% of maximal workload, 30 min/day, 5 days/week for 8 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control population (age-matched)
Number of subjects: 8
Study: 11789085

Group type: EXPERIMENTAL
Intervention: 1 mg micronized E2 daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9205790

Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine (NE) levels during flashbacks in flashbackers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels during flashbacks in flashbackers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma NE levels in subjects with persistent methamphetamine psychosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Plasma MHPG levels in nonflashbackers
Number of subjects: 50
Study: 8039273

Group type: COMPARATOR
Intervention: Blood pressure on entry to the trial (162/98 mmHg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entry blood pressure (BP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entry BP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pressor effect on BP
Number of subjects: 0
Study: 2459655

Group type: EXPERIMENTAL
Intervention: Bovine surfactant treatment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 4147246

Group type: EXPERIMENTAL
Intervention: Ro 3‐3528, a non‐selective β‐adrenoceptor blocking drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (implied as a comparison)
Number of subjects: 0
Study: 31383692

Group type: EXPERIMENTAL
Intervention: Prenatal interventions (not specified in detail)
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Postnatal interventions (not specified in detail)
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Maternal anthropometry and parental education (not specified in detail)
Number of subjects: 2723
Study: 28425575

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (9 of 50000 IU cholecalciferol capsules for 9 weeks taken at weekly intervals)
Number of subjects: 580
Study: 27979579

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg with weekly increase to 3.0 mg for the last week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 21
Study: 24103498

Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBI) scheme
Number of subjects: 0
Study: 21891886

Group type: EXPERIMENTAL
Intervention: Light cure glass ionomer (Group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Light cure glass ionomer (Group II)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flowable compomer (Group III)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flowable compomer (Group IV)
Number of subjects: 100
Study: 19521742

Group type: EXPERIMENTAL
Intervention: Routine filterwire distal protection
Number of subjects: 344

Group type: COMPARATOR
Intervention: Standard PCI (Control)
Number of subjects: 344
Study: 17920501

Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Headgear/Biteplane
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Observation Group
Number of subjects: 261

Group type: COMPARATOR
Intervention: Full orthodontic treatment (after phase 1)
Number of subjects: 261
Study: 15121349

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention
Number of subjects: 268
Study: 11232942

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histologic grading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-phase analysis
Number of subjects: 0
Study: 9691529

Group type: EXPERIMENTAL
Intervention: Accent Method (AM) including voice hygiene advice plus accent exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voice hygiene advice only
Number of subjects: 0
Study: 7834993

Group type: EXPERIMENTAL
Intervention: 6 h primed constant infusion of NaH13CO3 combined with a euglycaemic hyperinsulinaemic clamp for the last 3 h (study 1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 6 h primed constant infusion of NaH13CO3 alone (study 2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 6 h infusion of normal saline combined with a hyperinsulinaemic clamp for the last 3 h (study 3)
Number of subjects: 6
Study: 3046537

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled beta agonist
Number of subjects: 0
Study: 30283403

Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg BD
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg BD
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Melatonin 8 mg BD
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All doses of melatonin combined
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All groups (including melatonin and placebo)
Number of subjects: 160
Study: 27188688

Group type: EXPERIMENTAL
Intervention: Mixed-gender Body Project (MG)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Female-only Body Project (FO)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 185
Study: 24754974

Group type: EXPERIMENTAL
Intervention: Standard treatment (systemic and narrative group psychotherapy) with feedback intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard treatment only (no feedback)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Standard treatment with feedback intervention
Number of subjects: 128
Study: 23001433

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20519875

Group type: EXPERIMENTAL
Intervention: miglitol
Number of subjects: 11

Group type: COMPARATOR
Intervention: voglibose
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 18402652

Group type: EXPERIMENTAL
Intervention: Laryngeal tube suction for single use (LTS-D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bag-mask ventilation (BMV)
Number of subjects: 0
Study: 16771893

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control group (written health risk information materials)
Number of subjects: 342
Study: 14964737

Group type: EXPERIMENTAL
Intervention: Intramuscular bupivacaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous midazolam (0.1 mg/kg) with control (saline)
Number of subjects: 150
Study: 10607768

Group type: EXPERIMENTAL
Intervention: Nocturnal haemodialysis (NHD)
Number of subjects: 10
Study: 9562521

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Tracking of serum lipoprotein (a) concentrations
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Lowest and highest lipoprotein (a) quintiles at 13 months
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Contribution of lipoprotein (a) cholesterol to total cholesterol
Number of subjects: 430
Study: 7524921

Group type: EXPERIMENTAL
Intervention: Retroperitoneal lymph-node dissection (RPLND)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Retroperitoneal lymph-node dissection (RPLND) without adjuvant chemotherapy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Overall survival with cisplatin-based chemotherapy
Number of subjects: 174
Study: 3314793

Group type: EXPERIMENTAL
Intervention: Wide excision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 0
Study: 29194180

Group type: EXPERIMENTAL
Intervention: ADL retraining during PTA
Number of subjects: 104

Group type: COMPARATOR
Intervention: No ADL retraining in PTA (treatment as usual, TAU)
Number of subjects: 104
Study: 27522321

Group type: EXPERIMENTAL
Intervention: Single-session, computer-assisted anxiety sensitivity intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 104
Study: 25403311

Group type: EXPERIMENTAL
Intervention: Pelubiprofen
Number of subjects: 145

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 145
Study: 24024319

Group type: EXPERIMENTAL
Intervention: Dongchongxiacao (Cordyceps) treatment (n = 52)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Basic treatment (n = 51)
Number of subjects: 103
Study: 21417969

Group type: EXPERIMENTAL
Intervention: Extracapsular dissection (ED)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Superficial parotidectomy (SP)
Number of subjects: 41
Study: 18412647

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg x kg(‐1)
Number of subjects: 500

Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 500
Study: 16641342

Group type: EXPERIMENTAL
Intervention: Reteplase plus abciximab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Urokinase plus abciximab
Number of subjects: 120
Study: 12891278

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 2
Study: 10781654

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (800 I.U. per day for 12 weeks)
Number of subjects: 0
Study: 8768815

Group type: EXPERIMENTAL
Intervention: Terbinafine cream during 1 week
Number of subjects: 263

Group type: COMPARATOR
Intervention: Miconazole cream during 4 weeks
Number of subjects: 263
Study: 1424849

Group type: EXPERIMENTAL
Intervention: Bennett Cascade 2 humidifier
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fisher‐Paykel MR 460
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pall Ultipor filter (HME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hygrobac filter (HME)
Number of subjects: 0
Study: 3954590

Group type: EXPERIMENTAL
Intervention: Shoulder traction device
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard technique (manual traction)
Number of subjects: 48
Study: 29705475

Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Number of subjects: 60
Study: 28074135

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 µg twice daily
Number of subjects: 1792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1792
Study: 25459036

Group type: COMPARATOR
Intervention: TF-TAVR in the NRCA registry
Number of subjects: 1438
Study: 22391074

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) with sphenopalatine ganglion (SPG) blocks
Number of subjects: 70

Group type: COMPARATOR
Intervention: General anesthesia (GA) alone
Number of subjects: 70
Study: 20403714

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 100
Study: 18308903

Group type: EXPERIMENTAL
Intervention: Cognitive remediation program (24 hours of computerized practice over a 12-week period and a weekly discussion group)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Number of subjects: 85

Group type: COMPARATOR
Intervention: Computer control group (similar hours of staff and computer exposure without cognitive training exercises)
Number of subjects: 85
Study: 15983466

Group type: EXPERIMENTAL
Intervention: Topical 2% amitriptyline
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Topical 1% ketamine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Topical 2% amitriptyline-1% ketamine combined
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 12406832

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg chewable tablets)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 10521866

Group type: EXPERIMENTAL
Intervention: Screening intervention (not specified dosage or duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not screened)
Number of subjects: 0
Study: 7723712

Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole infusion
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 57
Study: 1951907

Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: No drainage (Control)
Number of subjects: 200
Study: 7283216

Group type: EXPERIMENTAL
Intervention: 0.1 mg epinephrine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.3 mg epinephrine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5 mg epinephrine
Number of subjects: 32
Study: 31725476

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) treatment
Number of subjects: 25
Study: 28601691

Group type: EXPERIMENTAL
Intervention: Nurse-led transitional care intervention
Number of subjects: 199

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 199
Study: 26054141

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine (budesonide nasal spray and cetirizine tablets)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study: 23783065

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study: 22137413

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 306

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 306
Study: 19714953

Group type: EXPERIMENTAL
Intervention: Head and neck surgical oncology clinical practicum (Experimental Group, n=19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: General surgical unit (Control Group, n=18)
Number of subjects: 37